利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4 条记录 (耗时 0.08 秒)

    3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function
    3.
    发明授权
    3,4-diaminoquinoline and 3,4-diamino-5,6,7,8-tetrahydroquinoline compounds useful for improving psychoneural function 失效
    可用于改善精神功能的3,4-二氨基喹啉和3,4-二氨基-5,6,7,8-四氢喹啉化合物

    公开(公告)号：US5019574A

    公开(公告)日：1991-05-28

    申请号：US414170

    申请日：1989-09-28

    申请人： Yutaka Miura ,  Mitsutaka Yoshida ,  Yasuo Fujimura ,  Sakae Takaku ,  Yukifumi Noda

    发明人： Yutaka Miura ,  Mitsutaka Yoshida ,  Yasuo Fujimura ,  Sakae Takaku ,  Yukifumi Noda

    IPC分类号： C07D213/73 ,  C07D213/74 ,  C07D215/42

    CPC分类号： C07D213/73 ,  C07D213/74 ,  C07D215/42

    摘要： 4-aminopyridine derivatives represented by the general formula: ##STR1## [wherein R.sub.1 is a hydrogen atom, a hydroxyl group, a linear or branched lower alkyl group or a cycloalkyl group which may be substituted by a hydroxyl group, a lower alkoxy group, a lower alkyl or a cycloalkyl group which contains a carbonyl group, a morpholino group or a group --NH--B (where B is a lower alkyl group, a cycloalkyl group or a phenyl group); R.sub.2 and R.sub.3 which may be the same or different each represents a hydrogen atom, a lower alkyl group or a loweralkylcarbonyl group, or when taken together, form an azacycloalkyl group, a morpholino group or an N-methylpiperazinyl group together with the nitrogen atom; R.sub.4 and R.sub.5 each represents a hydrogen atom, or when taken together with the ring A, form a quinoline ring or a 5,6,7,8-tetrahydroquinoline ring, provided that when each of R.sub.1, R.sub.4 and R.sub.5 is a hydrogen atom, R.sub.2 and R.sub.3 are neither a hydrogen atom nor a methyl group at the same time, and when R.sub.1 is a hydrogen atom and R.sub.4 and R.sub.5 taken together with the ring A form a quinoline ring, R.sub.2 and R.sub.3 are neither a hydrogen atom nor an ethyl group at the same time], and an acid addition salts of said 4-aminopyridine derivatives. These compounds are useful as active ingredients in pharmaceutical compositions for improving psychoneural function, especially in the treatment of Alzheimer type dementia and promotion of mnemonic and learning performance.